» Articles » PMID: 30084838

Mast Cell Activation and KSHV Infection in Kaposi Sarcoma

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2018 Aug 8
PMID 30084838
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Kaposi sarcoma (KS) is a vascular tumor initiated by infection of endothelial cells (ECs) with KS-associated herpesvirus (KSHV). KS is dependent on sustained proinflammatory signals provided by intralesional leukocytes and continued infection of new ECs. However, the sources of these cytokines and infectious virus within lesions are not fully understood. Here, mast cells (MCs) are identified as proinflammatory cells within KS lesions that are permissive for, and activated by, infection with KSHV. Three validated MC lines were used to assess permissivity of MCs to infection with KSHV and to evaluate MCs activation following infection. Biopsies from 31 AIDS-KS cases and 11 AIDS controls were evaluated by IHC for the presence of MCs in KS lesions and assessment of MC activation state and infection with KSHV. Plasma samples from 26 AIDS-KS, 13 classic KS, and 13 healthy adults were evaluated for levels of MC granule contents tryptase and histamine. In culture, MCs supported latent and lytic KSHV infection, and infection-induced MC degranulation. Within KS lesions, MCs were closely associated with spindle cells. Furthermore, MC activation was extensive within patients with KS, reflected by elevated circulating levels of tryptase and a histamine metabolite. One patient with clinical signs of extensive MC activation was treated with antagonists of MC proinflammatory mediators, which resulted in a rapid and durable regression of AIDS-KS lesions. Using complimentary and studies we identify MCs as a potential long-lived reservoir for KSHV and a source of proinflammatory mediators within the KS lesional microenvironment. In addition, we identify MC antagonists as a promising novel therapeutic approach for KS. .

Citing Articles

The AIDS and Cancer Specimen Resource (ACSR): HIV malignancy specimens and data available at no cost.

Silver S, Schmelz M AIDS Res Ther. 2023; 20(1):61.

PMID: 37641153 PMC: 10464020. DOI: 10.1186/s12981-023-00558-4.


Exploring the interactions of antihistamine with retinoic acid receptor beta (RARB) by molecular dynamics simulations and genome-wide meta-analysis.

Kim M, Kulkarni V, Goode M, Sivesind T J Mol Graph Model. 2023; 124:108539.

PMID: 37331258 PMC: 10529808. DOI: 10.1016/j.jmgm.2023.108539.


Role of Histamine and Related Signaling in Kaposi's Sarcoma-Associated Herpesvirus Pathogenesis and Oncogenesis.

Chen J, Song J, Plaisance-Bonstaff K, Mu S, Post S, Dai L Viruses. 2023; 15(4).

PMID: 37112991 PMC: 10142667. DOI: 10.3390/v15041011.


Kaposi Sarcoma, a Trifecta of Pathogenic Mechanisms.

Rusu-Zota G, Manole O, Gales C, Porumb-Andrese E, Obada O, Mocanu C Diagnostics (Basel). 2022; 12(5).

PMID: 35626397 PMC: 9140574. DOI: 10.3390/diagnostics12051242.


Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review.

Hsieh C, Tsai T Dermatol Ther (Heidelb). 2021; 11(3):719-732.

PMID: 33846906 PMC: 8163952. DOI: 10.1007/s13555-021-00524-w.


References
1.
Mizuno H, Nakayama T, Miyata Y, Saito S, Nishiwaki S, Nakao N . Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib. Leukemia. 2012; 26(10):2269-76. DOI: 10.1038/leu.2012.81. View

2.
Punjabi A, Carroll P, Chen L, Lagunoff M . Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol. 2006; 81(5):2449-58. PMC: 1865938. DOI: 10.1128/JVI.01769-06. View

3.
Pantanowitz L, Schwartz E, Dezube B, Kohler S, Dorfman R, Tahan S . C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma. Appl Immunohistochem Mol Morphol. 2005; 13(2):162-6. DOI: 10.1097/00129039-200506000-00009. View

4.
Hagiwara K, Khaskhely N, Uezato H, Nonaka S . Mast cell "densities" in vascular proliferations: a preliminary study of pyogenic granuloma, portwine stain, cavernous hemangioma, cherry angioma, Kaposi's sarcoma, and malignant hemangioendothelioma. J Dermatol. 1999; 26(9):577-86. DOI: 10.1111/j.1346-8138.1999.tb02052.x. View

5.
Metz M, Maurer M . Mast cells--key effector cells in immune responses. Trends Immunol. 2007; 28(5):234-41. DOI: 10.1016/j.it.2007.03.003. View